Loading clinical trials...
Loading clinical trials...
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2a Study With an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily NNC0090-2746 in Type 2 Diabetic Patients Inadequately Controlled With Metformin
Conditions
Interventions
Liraglutide
Metformin
+2 more
Locations
20
United States
Novo Nordisk Investigational Site
Chino, California, United States
Novo Nordisk Investigational Site
Hawaiian Gardens, California, United States
Novo Nordisk Investigational Site
Los Angeles, California, United States
Novo Nordisk Investigational Site
Spring Valley, California, United States
Novo Nordisk Investigational Site
Hialeah, Florida, United States
Novo Nordisk Investigational Site
Port Orange, Florida, United States
Start Date
August 18, 2014
Primary Completion Date
September 15, 2015
Completion Date
September 15, 2015
Last Updated
July 21, 2020
NCT07224321
NCT01399385
NCT07536516
NCT06513026
NCT07340320
NCT07232537
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions